Fatigue News and Research

RSS

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study.

16 May 2014

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that principal investigator, Srdan Verstovsek, MD, PhD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 2, 2014 at the American Society for Clinical Oncology 2014 Annual Meeting.

15 May 2014

In-office treatment using balloon sinus dilation is as effective as FESS for chronic sinusitis

New results from a randomized trial published in the American Journal of Rhinology and Allergy demonstrate the benefits of in-office balloon dilation for sufferers of chronic sinusitis.

15 May 2014

Novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis

A novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis (PVNS), a rare neoplastic joint disorder, according to new phase I data from Memorial Sloan Kettering Cancer Center and other institutions highlighted to media today in advance of the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will take place from May 30 to June 3 in Chicago.

15 May 2014

Phase I study reveals abemaciclib drug shows evidence of single-agent activity in NSCLC patients

Abemaciclib, an oral drug administered twice daily, currently in development by Eli Lilly and Company (NYSE: LLY), has shown evidence of single-agent activity in patients with advanced non-small cell lung cancer in a Phase I study released ahead of the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, Ill.

15 May 2014

Vitamin B12 shot does not boost energy, metabolism, says study

Feeling sluggish? Gaining weight? What you need is a shot in the arm, claim advertisers for trendy vitamin B12 injections.

14 May 2014

UNF Professor discovers 2 Lyme disease bacterial species that infect human patients

Dr. Kerry Clark, associate professor of public health at the University of North Florida in Jacksonville, and his colleagues have found additional cases of Lyme disease in patients from several states in the southeastern U.S. These cases include two additional Lyme disease Borrelia species recently identified in patients in Florida and Georgia.

14 May 2014

CNS stimulant no more effective than placebo for alleviating lung cancer fatigue

Patients with advanced non-small-cell lung cancer who received the central nervous system stimulant modafinil reported no greater reduction in fatigue than patients given placebo, show study results.

13 May 2014

Vestiage launches new product designed specifically to women having low sex drive

Vestiage™, Inc., the healthy-aging company, is proud to announce the completed development and forthcoming launch of a new product designed specifically to address the issue of women's decreased libido and low sex drive.

13 May 2014

Pfizer reports positive results from rLP2086 Phase 2 study for invasive meningococcal disease

Pfizer Inc. announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer's recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds.

12 May 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

7 May 2014

Social worker has potential to reduce functional decline of people with mild traumatic brain injury

More than a million people are treated for mild traumatic brain injuries in U.S. hospitals and emergency rooms each year. Yet few receive appropriate psychological and social follow-up care that can make the difference in whether or not they fully recover.

7 May 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

6 May 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.

6 May 2014

Study shows room for improvement in medical management of women with PAD

Women face greater limits on their lifestyle and have more severe symptoms as a result of peripheral artery disease (PAD), but minimally invasive procedures used to unclog arteries are just as successful as in men.

6 May 2014

Teva's SYNRIBO for injection receives FDA approval for home administration

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and Instructions for Use.

6 May 2014

UH biomedical engineer receives ALR grant to study cause of lupus nephritis

In the U.S. alone, more than 1.5 million people have lupus, a chronic autoimmune disease in which the immune system turns against itself, attacking a person's healthy tissue, cells and organs. The symptoms can range from debilitating pain and fatigue to organ failure.

6 May 2014

Study examines potential benefits of low fat diet on management of MS

People with multiple sclerosis who for one year followed a plant-based diet very low in saturated fat had much less MS-related fatigue at the end of that year - and significantly less fatigue than a control group of people with MS who didn't follow the diet, according to an Oregon Health & Science University study being presented today at the American Academy of Neurology's annual meeting in Philadelphia, Pa.

2 May 2014

Richard M. Ross Heart Hospital docs implanted smallest heart pacemaker in Columbus woman

It's about the size of a large vitamin pill and, for the first time in Ohio, the smallest heart pacemaker available is being tested at The Ohio State University Wexner Medical Center.

From Medtronic 2 May 2014

Fatigue News and Research

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

In-office treatment using balloon sinus dilation is as effective as FESS for chronic sinusitis

Novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis

Phase I study reveals abemaciclib drug shows evidence of single-agent activity in NSCLC patients

Vitamin B12 shot does not boost energy, metabolism, says study

UNF Professor discovers 2 Lyme disease bacterial species that infect human patients

CNS stimulant no more effective than placebo for alleviating lung cancer fatigue

Vestiage launches new product designed specifically to women having low sex drive

Pfizer reports positive results from rLP2086 Phase 2 study for invasive meningococcal disease

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma

Social worker has potential to reduce functional decline of people with mild traumatic brain injury

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Study shows room for improvement in medical management of women with PAD

Teva's SYNRIBO for injection receives FDA approval for home administration

UH biomedical engineer receives ALR grant to study cause of lupus nephritis

Study examines potential benefits of low fat diet on management of MS

Richard M. Ross Heart Hospital docs implanted smallest heart pacemaker in Columbus woman

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News